Q-omics provides the consensus-scored JAZF1 profile across patient tissues and cancer cell-line models. JAZF1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, JAZF1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, JAZF1 RNA expression shows 18,719 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KIRC, and UVM as cancer lineages where JAZF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JAZF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JAZF1 survival associations across molecular data types. JAZF1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JAZF1 RNA expression–survival associations across cancer types. High JAZF1 expression shows unfavorable associations in STAD, KIRP and BLCA, but favorable associations in SKCM, KIRC and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify STAD as the clearest survival context for JAZF1 RNA expression.
This table summarizes JAZF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for JAZF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JAZF1 shows lower tumor expression in BLCA, LUSC, COAD and KICH and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher JAZF1 RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with JAZF1 in patient tissues and cancer cell lines. In patient samples, JAZF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, JAZF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
